A phase II study of BI 771716
Latest Information Update: 06 Sep 2024
At a glance
- Drugs CDR 202 (Primary)
- Indications Dry macular degeneration
- Focus Therapeutic Use
- 06 Sep 2024 New trial record
- 05 Sep 2024 According to a Boehringer Ingelheim media release, the preparation for the Phase II trial is now underway, with an expected start date in early 2025.